Anxiety and Depression Effects During Drug Provocation Test

Laura Michelina Losappio, Alessandra Cappai, Alessandra Arcolaci, Iuliana Badiu, Patrizia Bonadonna, Elisa Boni, Claudia Bussolino, Marco Caminati, Pietro Galati, Enrico Heffler, Rossella Intravaia, Marina Mauro, Ilaria Massaro, Antonino Romano, Gabriele Rumi, Anna Parolo, Stefano Pizzimenti, Michele Nichelatti, Elide Anna Pastorello

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Drug provocation test (DPT) represents the gold standard for the diagnosis of drug allergy. A DPT can be performed in a single-blind placebo-controlled manner. In anxiety and depressive disorders, patients need to be evaluated to understand the nature of placebo reactions. Objective: The aim of this study was to evaluate the psychological profile of patients with reactions to placebo during a DPT. Methods: We consecutively enrolled patients with suspected drug allergy undergoing a DPT preceded by the administration of the placebo. All patients underwent the Hospital Anxiety and Depression Scale (HADS), a questionnaire aimed to identify anxiety and depression, before the challenge test. Results: A total of 196 patients were enrolled into this study: 8 (4%) patients resulted positive to the DPT, 60 (30.6%) demonstrated anxiety or depression based on the HADS, and 54 had at least 1 placebo reaction during drug provocation. There were statically significant correlations between the positivity of the HADS and the finding of a placebo reaction (Fisher's exact test: P <.001), and between the latter and a history of severe reactions to drug (Fisher's exact test: P <.001). Conclusions: There is a significant and strong correlation between the loss of psychic equilibrium and the development of a placebo reaction during a DPT. We suggest the use the HADS or other validated questionnaire in clinical practice before a DPT to evaluate the possible psychiatric components.

Original languageEnglish
Pages (from-to)1637-1641
Number of pages5
JournalJournal of Allergy and Clinical Immunology: In Practice
Volume6
Issue number5
DOIs
Publication statusPublished - Sep 1 2018

Fingerprint

Anxiety
Depression
Placebos
Pharmaceutical Preparations
Drug Hypersensitivity
Depressive Disorder
Anxiety Disorders
Psychiatry
Psychology

Keywords

  • Anxiety
  • Depression
  • Drug allergy
  • Drug provocation test
  • Placebo

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Losappio, L. M., Cappai, A., Arcolaci, A., Badiu, I., Bonadonna, P., Boni, E., ... Pastorello, E. A. (2018). Anxiety and Depression Effects During Drug Provocation Test. Journal of Allergy and Clinical Immunology: In Practice, 6(5), 1637-1641. https://doi.org/10.1016/j.jaip.2017.12.005

Anxiety and Depression Effects During Drug Provocation Test. / Losappio, Laura Michelina; Cappai, Alessandra; Arcolaci, Alessandra; Badiu, Iuliana; Bonadonna, Patrizia; Boni, Elisa; Bussolino, Claudia; Caminati, Marco; Galati, Pietro; Heffler, Enrico; Intravaia, Rossella; Mauro, Marina; Massaro, Ilaria; Romano, Antonino; Rumi, Gabriele; Parolo, Anna; Pizzimenti, Stefano; Nichelatti, Michele; Pastorello, Elide Anna.

In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 6, No. 5, 01.09.2018, p. 1637-1641.

Research output: Contribution to journalArticle

Losappio, LM, Cappai, A, Arcolaci, A, Badiu, I, Bonadonna, P, Boni, E, Bussolino, C, Caminati, M, Galati, P, Heffler, E, Intravaia, R, Mauro, M, Massaro, I, Romano, A, Rumi, G, Parolo, A, Pizzimenti, S, Nichelatti, M & Pastorello, EA 2018, 'Anxiety and Depression Effects During Drug Provocation Test', Journal of Allergy and Clinical Immunology: In Practice, vol. 6, no. 5, pp. 1637-1641. https://doi.org/10.1016/j.jaip.2017.12.005
Losappio, Laura Michelina ; Cappai, Alessandra ; Arcolaci, Alessandra ; Badiu, Iuliana ; Bonadonna, Patrizia ; Boni, Elisa ; Bussolino, Claudia ; Caminati, Marco ; Galati, Pietro ; Heffler, Enrico ; Intravaia, Rossella ; Mauro, Marina ; Massaro, Ilaria ; Romano, Antonino ; Rumi, Gabriele ; Parolo, Anna ; Pizzimenti, Stefano ; Nichelatti, Michele ; Pastorello, Elide Anna. / Anxiety and Depression Effects During Drug Provocation Test. In: Journal of Allergy and Clinical Immunology: In Practice. 2018 ; Vol. 6, No. 5. pp. 1637-1641.
@article{d0370876f4eb48998a9349d38122f71b,
title = "Anxiety and Depression Effects During Drug Provocation Test",
abstract = "Background: Drug provocation test (DPT) represents the gold standard for the diagnosis of drug allergy. A DPT can be performed in a single-blind placebo-controlled manner. In anxiety and depressive disorders, patients need to be evaluated to understand the nature of placebo reactions. Objective: The aim of this study was to evaluate the psychological profile of patients with reactions to placebo during a DPT. Methods: We consecutively enrolled patients with suspected drug allergy undergoing a DPT preceded by the administration of the placebo. All patients underwent the Hospital Anxiety and Depression Scale (HADS), a questionnaire aimed to identify anxiety and depression, before the challenge test. Results: A total of 196 patients were enrolled into this study: 8 (4{\%}) patients resulted positive to the DPT, 60 (30.6{\%}) demonstrated anxiety or depression based on the HADS, and 54 had at least 1 placebo reaction during drug provocation. There were statically significant correlations between the positivity of the HADS and the finding of a placebo reaction (Fisher's exact test: P <.001), and between the latter and a history of severe reactions to drug (Fisher's exact test: P <.001). Conclusions: There is a significant and strong correlation between the loss of psychic equilibrium and the development of a placebo reaction during a DPT. We suggest the use the HADS or other validated questionnaire in clinical practice before a DPT to evaluate the possible psychiatric components.",
keywords = "Anxiety, Depression, Drug allergy, Drug provocation test, Placebo",
author = "Losappio, {Laura Michelina} and Alessandra Cappai and Alessandra Arcolaci and Iuliana Badiu and Patrizia Bonadonna and Elisa Boni and Claudia Bussolino and Marco Caminati and Pietro Galati and Enrico Heffler and Rossella Intravaia and Marina Mauro and Ilaria Massaro and Antonino Romano and Gabriele Rumi and Anna Parolo and Stefano Pizzimenti and Michele Nichelatti and Pastorello, {Elide Anna}",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.jaip.2017.12.005",
language = "English",
volume = "6",
pages = "1637--1641",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "American Academy of Allergy, Asthma and Immunology",
number = "5",

}

TY - JOUR

T1 - Anxiety and Depression Effects During Drug Provocation Test

AU - Losappio, Laura Michelina

AU - Cappai, Alessandra

AU - Arcolaci, Alessandra

AU - Badiu, Iuliana

AU - Bonadonna, Patrizia

AU - Boni, Elisa

AU - Bussolino, Claudia

AU - Caminati, Marco

AU - Galati, Pietro

AU - Heffler, Enrico

AU - Intravaia, Rossella

AU - Mauro, Marina

AU - Massaro, Ilaria

AU - Romano, Antonino

AU - Rumi, Gabriele

AU - Parolo, Anna

AU - Pizzimenti, Stefano

AU - Nichelatti, Michele

AU - Pastorello, Elide Anna

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Background: Drug provocation test (DPT) represents the gold standard for the diagnosis of drug allergy. A DPT can be performed in a single-blind placebo-controlled manner. In anxiety and depressive disorders, patients need to be evaluated to understand the nature of placebo reactions. Objective: The aim of this study was to evaluate the psychological profile of patients with reactions to placebo during a DPT. Methods: We consecutively enrolled patients with suspected drug allergy undergoing a DPT preceded by the administration of the placebo. All patients underwent the Hospital Anxiety and Depression Scale (HADS), a questionnaire aimed to identify anxiety and depression, before the challenge test. Results: A total of 196 patients were enrolled into this study: 8 (4%) patients resulted positive to the DPT, 60 (30.6%) demonstrated anxiety or depression based on the HADS, and 54 had at least 1 placebo reaction during drug provocation. There were statically significant correlations between the positivity of the HADS and the finding of a placebo reaction (Fisher's exact test: P <.001), and between the latter and a history of severe reactions to drug (Fisher's exact test: P <.001). Conclusions: There is a significant and strong correlation between the loss of psychic equilibrium and the development of a placebo reaction during a DPT. We suggest the use the HADS or other validated questionnaire in clinical practice before a DPT to evaluate the possible psychiatric components.

AB - Background: Drug provocation test (DPT) represents the gold standard for the diagnosis of drug allergy. A DPT can be performed in a single-blind placebo-controlled manner. In anxiety and depressive disorders, patients need to be evaluated to understand the nature of placebo reactions. Objective: The aim of this study was to evaluate the psychological profile of patients with reactions to placebo during a DPT. Methods: We consecutively enrolled patients with suspected drug allergy undergoing a DPT preceded by the administration of the placebo. All patients underwent the Hospital Anxiety and Depression Scale (HADS), a questionnaire aimed to identify anxiety and depression, before the challenge test. Results: A total of 196 patients were enrolled into this study: 8 (4%) patients resulted positive to the DPT, 60 (30.6%) demonstrated anxiety or depression based on the HADS, and 54 had at least 1 placebo reaction during drug provocation. There were statically significant correlations between the positivity of the HADS and the finding of a placebo reaction (Fisher's exact test: P <.001), and between the latter and a history of severe reactions to drug (Fisher's exact test: P <.001). Conclusions: There is a significant and strong correlation between the loss of psychic equilibrium and the development of a placebo reaction during a DPT. We suggest the use the HADS or other validated questionnaire in clinical practice before a DPT to evaluate the possible psychiatric components.

KW - Anxiety

KW - Depression

KW - Drug allergy

KW - Drug provocation test

KW - Placebo

UR - http://www.scopus.com/inward/record.url?scp=85040452887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040452887&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2017.12.005

DO - 10.1016/j.jaip.2017.12.005

M3 - Article

AN - SCOPUS:85040452887

VL - 6

SP - 1637

EP - 1641

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

SN - 2213-2198

IS - 5

ER -